AnchorWatch Trust Company, a Nevada-chartered custodian, has launched Bitcoin custody services with a monthly fee capped at $10,000 regardless of Bitcoin price or deposit size. It offers two custody models: Flagship Custody where AnchorWatch holds all keys, and Multi-Institution Custody with shared control among AnchorWatch, BitGo, and CoinCorner. Optional insurance backed by Lloyd's of London covers up to $370 million per individual client, protecting against theft, coercion, and fraud. This service targets wealthy holders and institutions needing qualified custody with strong security and insurance.
AnchorWatch Trust Company's new Bitcoin custody service is the subject, with Pluang market data providing context as of Oct 19, 2026 22:31 WIB. Among 50 major cryptocurrencies priced on Pluang, 41 rose and 8 fell today. Notable movers include GRT at Rp433 (+3.54%, 90% Sell / 10% Buy), SNX at Rp3.868 (+3.17%, 52% Sell / 48% Buy), and XRP at Rp23.517 (+3.09%, 49% Sell / 51% Buy).
Disc Medicine's stock surged 38% following positive Phase 3 trial results for its drug bitopertin, which showed efficacy and safety in treating erythropoietic protoporphyria. BMO Capital raised its price target from $100 to $120 and maintained an Out...
Qualcomm executive Ann C. Chaplin sold 1,827 shares of the company's stock for $319,268.25 under a Rule 10b5-1 trading plan, reducing her holdings by 6.62%. Qualcomm's stock price recently traded below its 50-day and 200-day moving averages, signalin...
BOK Financial is set to announce its Q3 2026 earnings after market close on October 19, with analysts forecasting earnings per share between $2.52 and $2.54 and revenue near $571 million. The company has a strong history of surpassing earnings estima...
AIBotics has completed the acquisition of NovaCore Labs' assets from PlayJamaica Limited, gaining technology, software, drones, mapping equipment, and customer contracts. This move expands AIBotics' platform in Jamaica and the Caribbean, enhancing AI...
EyePoint's stock dropped sharply after its DURAVYU treatment did not meet the primary endpoint in a Phase 3 trial for wet age-related macular degeneration (wet AMD). Although DURAVYU showed some vision improvement and reduced the need for additional ...
